12th Sep 2013 10:33
LONDON (Alliance News) - Technology-commercialisation and investment group Imperial Innovations Group PLC Thursday said subsidiary Circassia has achieved successful results from a Phase II clinical study of its house dust-mite allergy treatment.
Circassia, a speciality biopharmaceutical company focused on allergy, said patients in Canada who received four doses of its treatment over 12 weeks had significantly improved allergy symptoms one year after the start of the trial compared with placebo, meeting the study's long-term primary endpoint.
Circassia has submitted the study results for presentation at a unnamed scientific conference.
Imperial Innovations shares were trading at 274.10 pence Thursday morning, down 0.40 pence, or 0.2%.
By Anthony Tshibangu; [email protected]; @AnthonyAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Imperial Innovations Group